Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;2011(4):CD009069.
doi: 10.1002/14651858.CD009069.

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors

Marc Arbyn  1 , Andrew Bryant  2 , Philippe Beutels  3 , Pierre Pl Martin-Hirsch  4 , Evangelos Paraskevaidis  5 , Elke Van Hoof  6 , Marc Steben  7 , Youlin Qiao  8 , Fang-Hui Zhao  8 , Achim Schneider  9 , Andreas Kaufmann  10 , Joakim Dillner  11 , Lauri Markowitz  12 , Allan Hildesheim  13
Affiliations

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors

Marc Arbyn et al. Cochrane Database Syst Rev. 2011.

Update in

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To evaluate the immunogenicity, clinical efficacy, and safety of prophylactic HPV vaccines in females. The assessment of clinical efficacy will address protection against HPV infection (for homologous and heterologous HPV types), against re-infection, against cervical cancer and its precursors (high-grade CIN (grade 2 or grade 3), adenocarcinoma in situ) in women previously not exposed to HPV infection (negative at enrolment for both HPV DNA and antibodies against the vaccine HPV types). We will assess clinical effectiveness by evaluating outcomes in all women, irrespective of the HPV DNA or serology status at enrolment. Evaluation by fine age and time since sexual debut categories is also planned.

PubMed Disclaimer

Comment in

References

    1. Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. Journal of Clinical Virology. 2007;38(3):189–97. - PubMed
    1. Arbyn M, Rebolj M, De Kok IM, Becker N, O’Reilly M, Andrae B. The challenges for organising cervical screening programmes in the 15 old member states of the European Union. European Journal of Cancer. 2009;45(15):2671–8. - PubMed
    1. Arbyn M, Raifu AO, Bray F, Weiderpass E, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. European Journal of Cancer. 2009;45(15):2640–8. - PubMed
    1. Ault KA, Giuliano AR, Edwards RP, Tamms G, Kim LL, Smith JF, et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine. 2004;22(0264-410X, 23-24):3004–7. - PubMed
    1. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369(9576):1861–8. - PubMed

LinkOut - more resources